Biotech companies are now in a race to go beyond the limitations of existing targeted therapies either by finding complementary treatments or by combining already approved therapies to synergize their effect
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kling, J. Bundling next-generation cancer therapies for synergy. Nat Biotechnol 24, 871–872 (2006). https://doi.org/10.1038/nbt0806-871
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0806-871